 |
|
|
| |
100% SVR12 in Japanese Patients With Chronic Genotype 1 Hepatitis C Virus Infection Receiving Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks: Results From a Multicenter Phase 3 Study
|
| |
| |
Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
Masashi Mizokami,1 Tetsuo Takehara,2 Osamu Yokosuka,3 Naoya Sakamoto,4 Masaaki Korenaga,1 Hitoshi Mochizuki,5 Kunio Nakane,6 Hirayuki Enomoto,7 Mikio Yanase,1 Hidenori Toyoda,8 Fusao Ikeda,9 Takuya Genda,10 Takeji Umemura,11 Hiroshi Yatsuhashi,12
Tatsuya Ide,13 Nobuo Toda,14 Kazushige Nirei,15 Yoshiyuki Ueno,16 Yoichi Nishigaki,17 Juan Betular,18 Bing Gao,18 Hadas Dvory-Sobol,18 Akinobu Ishizaki,18 Masa Omote,18 Phillip S. Pang,18 Steven J. Knox,18 William T. Symonds,18 John G. McHutchison,18 Namiki Izumi,19 Masao Omata5
1National Center for Global Health and Medicine, Tokyo, Japan; 2Osaka University, Osaka, Japan; 3Chiba University, Chiba, Japan; 4Hokkaido University, Hokkaido, Japan; 5Yamanashi Prefectural Hospital Organization, Yamanashi, Japan; 6Akita City Hospital, Akita, Japan; 7Hyogo College of Medicine, Hyogo, Japan; 8Ogaki Municipal Hospital, Gifu, Japan; 9Okayama University, Okayama, Japan;
10Juntendo University, Tokyo, Japan; 11Shinshu University, Nagano, Japan; 12National Hospital Organization Nagasaki Medical Center, Nagasaki, Japan; 13Kurume University, Kurume, Japan; 14Mitsui Memorial Hospital, Tokyo, Japan; 15Nihon University, Tokyo, Japan; 16Yamagata University, Yamagata, Japan; 17Gifu Municipal Hospital, Gifu, Japan; 18Gilead Sciences, Inc., Foster City, CA; 19Musashino Red Cross Hospital, Tokyo, Japan
|
| |
|
|
|
|
|
